NeoGenomics (NEO) has purchased a UG 100 sequencer to use in its UK innovation center in a collaboration with Ultima Genomics. The financial details were not disclosed.
NeoGenomics will use the UG 100, which provides genome sequencing capabilities, to enable the development of tests focused on cancer care, Ultima Genomics said in a statement Tuesday.
Price: 7.47, Change: -2.50, Percent Change: -25.08
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.